Prostate Cancer | Disease Landscape and Forecast | G7 | 2020

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson & Johnson / Janssen Biotech / Janssen-Cilag / AstraZeneca) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). However, the use of second-generation hormonal agents has expanded beyond mCRPC, and they are being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with two PARP inhibitors (Johnson & Johnson’s Zejula and Pfizer’s Talzenna), three immune checkpoint inhibitors (Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo, Bristol Myers Squibb / Ono Pharmaceutical’s Yervoy, Merck Sharp and Dohme’s Keytruda), two kinase inhibitors (Array BioPharma / Roche / Genentech / Chugai’s ipatasertib and AstraZeneca’s capivasertib), one radioligand therapy (Novartis’s 177Lu-PSMA-617), and one angiogenesis inhibitor (Exelixis / Takeda / Ipsen’s Cabometyx) in Phase III development.

Questions Answered

  • What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
  • How is prostate cancer currently managed, and how will treatment practices change in the future?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2029?
  • What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Bayer HealthCare, Clovis Oncology, Merck Sharp & Dohme, Exelixis, Ipsen, Takeda, AstraZeneca, Bristol Myers Squibb, Ono Pharmaceutical, Novartis, Myovant Sciences.

Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Nubeqa (darolutamide), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Cabometyx (cabozantinib), ipatasertib, relugolix, 177Lu-PSMA-617, capivasertib.

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

launch Related Market Assessment Reports